Linklaters advises Carlyle and PAI Partners on their acquisition of Theramex
Linklaters has advised global investment firms Carlyle (NASDAQ: CG) and PAI Partners on their acquisition of Theramex, the leading global specialty pharmaceuticals company focused on women’s health, from CVC Capital Partners.
Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018, and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health. The company now serves more than six million women in 57 countries across EMEA, APAC and South America.
The acquisition will enable Theramex to expand its diverse suite of products across existing and adjacent therapeutic areas and accelerate international expansion. This strategically builds on Carlyle’s long-term global focus on healthcare, a sector in which the firm has invested $15 billion to date. Meanwhile healthcare is one of PAI’s four core sectors of focus and its position in the market will further support Theramex’s ambitious growth trajectory.
The Linklaters team was led by Alex Woodward and Chris Boycott, partners in our private equity team, and supported by a specialist cross-practice global team, including Daniel Law (senior associate), Kim Low (managing associate), Tash Barrington (associate) and Santiago Menéndez (associate). The team were also supported by Jamie Coomber (counsel) who led on tax elements, Sinead Casey (partner) on employment matters, Yohan Liyanage (partner) on IP matters, Marly Didizian (partner) on TMT-related aspects, and Jana Hager (counsel) and Martin Otto (managing associate) on regulatory aspects.